Insights | Vantage Biomedical Partners

Regulatory

Jun 11, 2026 6 min

510(k) Predicate Strategy: How to Pick One That Survives Diligence

Your predicate is the most scrutinized early 510(k) decision. How to choose one that holds up in diligence — from public FDA data.

Reimbursement

Jun 4, 2026 6 min

The Reimbursement Question That Kills Medtech Deals

A cleared device no one pays for is the silent killer. How to answer the reimbursement question before you raise.

Fundraising

May 27, 2026 6 min

Angel & Seed Medtech Due Diligence: A Founder's Pre-Raise Checklist

Angels probe the same fault lines and decide fast. The pre-raise checklist with what to have ready for each.

Fundraising

May 21, 2026 7 min

Is Your Series A Medtech Actually Fundable? The 5 Risks Investors Find First

When an investor passes, it's rarely the science — it's a knowable risk that surfaced in diligence. Here are the five they check first, what the public record reveals, and how to close each before it costs you the round.

Due Diligence

May 12, 2026 9 min

Platform vs. Bolt-On: Why PE Healthcare Diligence Needs Different Playbooks

PE healthcare funds evaluate platforms and bolt-ons completely differently — but most diligence processes use the same playbook for both. That's where value destruction starts.

Due Diligence

May 5, 2026 8 min

The Strategic Acquirer's Blind Spot: Why Your Bankers Can't Assess Clinical Risk

Big 4 firms bring financial analysts and strategy associates. What they don't bring: anyone who has designed a medical device or navigated an FDA submission.

Case Insight

Apr 28, 2026 8 min

The TTO Commercialization Scorecard: Prioritizing Technologies That Actually Make It to Market

AUTM data shows only 5-10% of licensed technologies generate meaningful revenue. TTOs need a systematic framework for assessing commercial viability, not just technical novelty.

Case Insight

Apr 20, 2026 7 min

The First 100 Days: What PE Operating Partners Miss in Medtech Acquisitions

The standard PE 100-day playbook misses critical regulatory and clinical milestones. In our experience, the #1 cause of delayed value creation is internal quality issues not surfaced during diligence.

Due Diligence

Apr 14, 2026 8 min

Investor Readiness for Medical Device Founders: The 7 Questions VCs Will Ask That You're Not Prepared For

Most founders nail the pitch deck. But when VCs dig into diligence, they ask 7 questions that kill deals — and most founders haven't prepared answers.

Case Insight

Apr 7, 2026 6 min

How to Get Vantage Into Your University's Procurement System

University procurement is notoriously slow. Here's exactly how to navigate sole-source justifications, PO requirements, and budget approvals — with ready-to-use language.

Due Diligence

Mar 29, 2026 8 min

Manufacturing Due Diligence: The 10 Questions Every Investor Should Ask

Manufacturing risk is the silent killer of medical device investments. From single-source suppliers to quality system gaps, here are the 10 questions that separate informed investors from expensive lessons.

Regulatory

Mar 22, 2026 7 min

What Founders Get Wrong About Their First FDA Submission

Five costly mistakes we see repeatedly in founder assessments — from choosing the wrong regulatory pathway to underestimating biocompatibility requirements. Each one can add $2M+ and 12+ months to your timeline.

Regulatory

Mar 16, 2026 9 min

Cybersecurity in Connected Medical Devices: What FDA Now Requires

Post-PATCH Act, cybersecurity is no longer optional for connected devices. FDA now requires SBOMs, threat modeling, and coordinated vulnerability disclosure. Here's what investors and founders need to know.

Market Analysis

Mar 8, 2026 8 min

The GLP-1 Device Boom: Due Diligence on Medtech's Hottest Adjacency

The GLP-1 revolution is creating a $15B+ companion device opportunity. But not every 'GLP-1 adjacent' play is investable. Here's how to separate defensible positioning from hype.

Regulatory

Mar 1, 2026 7 min

De Novo vs 510(k): When the Shorter Path Actually Costs More

Founders default to 510(k) because it sounds faster. But forcing a weak predicate can cost more than De Novo would have. Here's the decision framework for choosing the right regulatory pathway.

Due Diligence

Feb 22, 2026 14 min

When the Pattern Holds: Real Companies, Real Failures, Real Lessons

From Exactech's bankruptcy to Butterfly Network's stalled growth, we map 9 real-world medtech failures to our proprietary Vantage Score framework.

Regulatory

Feb 13, 2026 9 min

FDA AI Deregulation: What Medical Device Founders Need to Know

The Trump administration's executive orders signal major shifts in FDA oversight of AI devices. We analyze what's actually changing versus political posturing.

Market Analysis

Feb 7, 2026 10 min

AI in Medical Devices: Separating Hype from Investment-Grade Innovation

Every pitch deck now features "physician-led" somewhere. But which AI medical device plays are actually defensible? We break down the regulatory realities.

Case Insight

Jan 30, 2026 5 min

Anatomy of a Failed Device Launch: Lessons from a $40M Write-Off

An anonymized deep-dive into how a well-funded surgical device company missed every adoption signal. The warning signs were there at Series A.

Regulatory

Jan 23, 2026 7 min

EU MDR Update: What the Latest Extensions Mean for US Companies

The EU MDR timeline continues to shift. We analyze the latest guidance and what it means for US device companies planning European market entry.

Due Diligence

Jan 16, 2026 9 min

Reimbursement Red Flags: The Questions VCs Forget to Ask

Clinical efficacy means nothing if payers won't cover it. We outline the reimbursement diligence framework that separates fundable opportunities.

Due Diligence

Jan 8, 2026 6 min

The Predicate Trap: Why 510(k) Strategy Kills More Deals Than You Think

We've seen it too many times: a promising device company builds their entire regulatory strategy on a predicate that was never appropriate.

Regulatory

Dec 30, 2025 8 min

FDA's Updated 510(k) Guidance: 5 Critical Changes Now in Effect

The FDA's updated 510(k) guidance introduces significant changes to predicate device selection and clinical data requirements. Here's what founders and investors need to understand.

Industry Analysis

January 2026 8 min

The Clinical Adoption Gap: Why 75% of Medical Devices Fail Post-Launch

Most medical device failures aren't technology failures — they're adoption failures. This analysis examines the structural reasons physicians resist new devices and how founders can assess adoption risk before committing capital to clinical trials.

Regulatory Intelligence

December 2025 6 min

Predicate Device Strategy: The $2M Mistake Most Startups Make

Choosing the wrong predicate device is the single most expensive regulatory error in medtech. We break down how to evaluate predicate risk, when De Novo is actually the faster path, and what the FDA's recent classification trends mean for your submission strategy.

TTO & Incubators

November 2025 7 min

From Lab to Market: Lessons from University Spinouts That Made It

We analyzed patterns across successful university-backed medical device companies to identify what separated them from the 90% that didn't reach commercialization. The findings point to three critical factors that most TTOs underweight in their portfolio decisions.

M&A Trends

2026 8 min

The Medical Device M&A Landscape: 2025 in Review and 2026 Outlook

Analysis of medical device M&A trends from 2025 and outlook for deal flow, valuation multiples, and strategic priorities in 2026.

Regulatory

Apr 2026 10 min

The AI Validation Gap: Why $18B in Healthcare AI Funding May Not Deliver

Healthcare AI raised $18 billion in Q1 2026. But most AI-enabled devices face a critical validation bottleneck that venture capital alone can't solve.

Clinical Risk

Mar 2026 8 min

The Clinical Adoption Gap

Most acquirers underestimate the hidden risk of clinical adoption failure. We analyze the patterns across 50+ failed integrations.

Regulatory

Apr 2026 11 min

FDA Regulatory Bottlenecks 2026: What Device Companies and Investors Need to Know

The FDA's Office of Device Evaluation faces capacity constraints that are creating multi-month delays. What this means for your timeline.

Due Diligence

2026 14 min

Medical Device Due Diligence: The Complete Framework for Investors and Acquirers

A comprehensive guide to medical device due diligence covering regulatory, clinical, technical, and commercial risk assessment. Built by a physician executive and biomedical engineer.

M&A Trends

Apr 2026 9 min

Medtech M&A 2026: Why Speed Is Killing Deal Quality

The medtech M&A market in early 2026 is running at unprecedented velocity. Large strategics are moving fast—sometimes too fast.

Regulatory

2026 7 min

Predicate Strategy Risks

The 510(k) pathway is faster than De Novo or PMA—but only if your predicate device strategy is correct. A wrong choice derails your timeline.

Digital Health

Apr 2026 9 min

RPM's New CPT Code: Engineering Implications for Device Manufacturers

CMS's new CPT 99445 code for device setup creates opportunities and requirements for remote patient monitoring device manufacturers. Engineering analysis.

Reimbursement

Apr 2026 10 min

The Skin Substitute Reimbursement Cliff: $19.6B Market in Crisis

CMS's 2025 OPPS changes have devastated skin substitute reimbursement. Analysis of the market impact and what it means for wound care investors.

Medical Device Intelligence

Due Diligence in 2026: What Healthcare Investors Are Actually Looking For

510(k) Predicate Strategy: How to Pick One That Survives Diligence

The Reimbursement Question That Kills Medtech Deals

Angel & Seed Medtech Due Diligence: A Founder's Pre-Raise Checklist

Is Your Series A Medtech Actually Fundable? The 5 Risks Investors Find First

Platform vs. Bolt-On: Why PE Healthcare Diligence Needs Different Playbooks

The Strategic Acquirer's Blind Spot: Why Your Bankers Can't Assess Clinical Risk

The TTO Commercialization Scorecard: Prioritizing Technologies That Actually Make It to Market

The First 100 Days: What PE Operating Partners Miss in Medtech Acquisitions

Investor Readiness for Medical Device Founders: The 7 Questions VCs Will Ask That You're Not Prepared For

How to Get Vantage Into Your University's Procurement System

Manufacturing Due Diligence: The 10 Questions Every Investor Should Ask

What Founders Get Wrong About Their First FDA Submission

Cybersecurity in Connected Medical Devices: What FDA Now Requires

The GLP-1 Device Boom: Due Diligence on Medtech's Hottest Adjacency

De Novo vs 510(k): When the Shorter Path Actually Costs More

When the Pattern Holds: Real Companies, Real Failures, Real Lessons

FDA AI Deregulation: What Medical Device Founders Need to Know

AI in Medical Devices: Separating Hype from Investment-Grade Innovation

Anatomy of a Failed Device Launch: Lessons from a $40M Write-Off

EU MDR Update: What the Latest Extensions Mean for US Companies

Reimbursement Red Flags: The Questions VCs Forget to Ask

The Predicate Trap: Why 510(k) Strategy Kills More Deals Than You Think

FDA's Updated 510(k) Guidance: 5 Critical Changes Now in Effect

The Clinical Adoption Gap: Why 75% of Medical Devices Fail Post-Launch

Predicate Device Strategy: The $2M Mistake Most Startups Make

From Lab to Market: Lessons from University Spinouts That Made It

The Medical Device M&A Landscape: 2025 in Review and 2026 Outlook

The AI Validation Gap: Why $18B in Healthcare AI Funding May Not Deliver

The Clinical Adoption Gap

FDA Regulatory Bottlenecks 2026: What Device Companies and Investors Need to Know

Medical Device Due Diligence: The Complete Framework for Investors and Acquirers

Medtech M&A 2026: Why Speed Is Killing Deal Quality

Predicate Strategy Risks

RPM's New CPT Code: Engineering Implications for Device Manufacturers

The Skin Substitute Reimbursement Cliff: $19.6B Market in Crisis

Stay Informed

Free Download: The Red Flags Guide

Need Custom Analysis?